CN103562723B - 用于识别肿瘤细胞的标记、方法及其试剂盒 - Google Patents

用于识别肿瘤细胞的标记、方法及其试剂盒 Download PDF

Info

Publication number
CN103562723B
CN103562723B CN201280021095.4A CN201280021095A CN103562723B CN 103562723 B CN103562723 B CN 103562723B CN 201280021095 A CN201280021095 A CN 201280021095A CN 103562723 B CN103562723 B CN 103562723B
Authority
CN
China
Prior art keywords
combination
cells
expression
prognosis
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280021095.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103562723A (zh
Inventor
曼吉里·巴克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oenkestm Pte Ltd
Original Assignee
Ou Are Telm Diagnostics (mauritius) Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ou Are Telm Diagnostics (mauritius) Pte Ltd filed Critical Ou Are Telm Diagnostics (mauritius) Pte Ltd
Publication of CN103562723A publication Critical patent/CN103562723A/zh
Application granted granted Critical
Publication of CN103562723B publication Critical patent/CN103562723B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
CN201280021095.4A 2011-03-27 2012-03-26 用于识别肿瘤细胞的标记、方法及其试剂盒 Active CN103562723B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2835CH2010 2011-03-27
IN2835/CHE/2010 2011-03-27
PCT/IB2012/051427 WO2012131564A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Publications (2)

Publication Number Publication Date
CN103562723A CN103562723A (zh) 2014-02-05
CN103562723B true CN103562723B (zh) 2017-04-26

Family

ID=46877646

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280021095.4A Active CN103562723B (zh) 2011-03-27 2012-03-26 用于识别肿瘤细胞的标记、方法及其试剂盒

Country Status (8)

Country Link
US (2) US8772455B2 (https=)
EP (1) EP2691776A4 (https=)
JP (1) JP2014515821A (https=)
KR (1) KR101621036B1 (https=)
CN (1) CN103562723B (https=)
AU (1) AU2012235767B2 (https=)
SG (1) SG193630A1 (https=)
WO (1) WO2012131564A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938583B2 (en) 2013-03-15 2018-04-10 Varian Medical Systems, Inc. Biomarkers for radiation treatment
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
FR3044680B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode de detection de cellules souches cancereuses
US10900968B2 (en) * 2016-05-24 2021-01-26 Oncostem Pte. Ltd. Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
CN106053172B (zh) * 2016-06-03 2018-10-30 浙江世纪康大医疗科技股份有限公司 一种edta抗原修复液
US10166406B2 (en) 2017-02-24 2019-01-01 Varian Medical Systems International Ag Radiation treatment planning and delivery using collision free regions
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101088089A (zh) * 2004-02-23 2007-12-12 鹿特丹伊拉斯姆斯大学医疗中心 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后
CN101583624A (zh) * 2006-09-29 2009-11-18 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005018789D1 (de) * 2004-08-10 2011-05-26 Cardiff Biolog Ltd Verfahren und kit zur prognose von brustkrebs
WO2007075672A2 (en) * 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
US7968169B2 (en) * 2007-08-07 2011-06-28 The Boeing Company Compound contoured composite beams and fabrication methods
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
WO2011007853A1 (ja) * 2009-07-14 2011-01-20 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体
WO2011113047A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for characterizing breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101088089A (zh) * 2004-02-23 2007-12-12 鹿特丹伊拉斯姆斯大学医疗中心 通过基因表达图形对急性粒细胞性白血病进行分类、诊断和预后
CN101583624A (zh) * 2006-09-29 2009-11-18 昂考梅德药品有限公司 用于诊断和治疗癌症的组合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Expression of CD133,PAX2,ESA,and GPR30 in invasive ductal breast carcinomas;Liu qun,et al.;《Chinese Medical Journal》;20091231;第122卷(第22期);第2763-2769页 *
Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers;Wendy W. Hwang-Verslues，et al.;《Plos One》;20091231;第4卷(第12期);第2页"Breast Cancer Cell Lines Heterogeneously Expressed Stem Cell Markers"部分，表1，附图5 *
微环境调控肾上腺皮质癌干细胞CD44、CXCR4、CD133和ABCG2表达的实验研究;罗佐杰;《中国博士学位论文全文数据库 医药卫生科技辑》;20100815;参见摘要，第43-44页第1.2.2.2节 *

Also Published As

Publication number Publication date
US8772455B2 (en) 2014-07-08
WO2012131564A1 (en) 2012-10-04
EP2691776A4 (en) 2015-04-15
CN103562723A (zh) 2014-02-05
EP2691776A1 (en) 2014-02-05
AU2012235767A1 (en) 2013-11-07
KR101621036B1 (ko) 2016-05-13
AU2012235767B2 (en) 2016-02-04
US20120244556A1 (en) 2012-09-27
KR20140015500A (ko) 2014-02-06
JP2014515821A (ja) 2014-07-03
US20140295459A1 (en) 2014-10-02
SG193630A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
CN103562723B (zh) 用于识别肿瘤细胞的标记、方法及其试剂盒
Buckup et al. Plectin is a regulator of prostate cancer growth and metastasis
Comstock et al. Impact of differential cyclin D1 expression and localisation in prostate cancer
Chien et al. Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer
Tsai et al. Reduction of global 5-hydroxymethylcytosine is a poor prognostic factor in breast cancer patients, especially for an ER/PR-negative subtype
Chen et al. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma
Birkhahn et al. Molecular markers for bladder cancer: the road to a multimarker approach
Zamay et al. DNA aptamers for the characterization of histological structure of lung adenocarcinoma
Huang et al. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non‐small cell lung cancer
Edden et al. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma
Erpolat et al. Hypoxia-related molecules HIF-1α, CA9, and osteopontin: Predictors of survival in patients with high-grade glioma
Tan et al. Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer
Wang et al. Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches
Liang et al. Expression of PTEN, androgen receptor, HER2/neu, cytokeratin 5/6, estrogen receptor-beta, HMGA2, and PLAG1 in salivary duct carcinoma
EP3403095B1 (en) Methods of assessing protein interactions between cells
Turato et al. S quamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity
Mathieu et al. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness
Sharifi et al. HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method
Grupp et al. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy
Schlomm et al. Molecular staging of prostate cancer in the year 2007
Shan et al. Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique
Ma et al. Phospholipase C‐γ1 expression correlated with cancer progression of potentially malignant oral lesions
Liu et al. Elevated expression of Thoc1 is associated with aggressive phenotype and poor prognosis in colorectal cancer
Zhao et al. Clinical significance of vimentin expression and Her‐2 status in patients with gastric carcinoma
Yang et al. Circulating Soluble Neuropilin‐1 in Patients with Early Cervical Cancer and Cervical Intraepithelial Neoplasia Can Be Used as a Valuable Diagnostic Biomarker

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193648

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1193648

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20200326

Address after: Shinka ha

Patentee after: Oenkestm Pte Ltd

Address before: Eberne, Mauritius

Patentee before: ONCOSTEM DIAGNOSTICS PVT. Ltd.

TR01 Transfer of patent right